Clicky

A New Reagent Improves the Production of Sulfur-Containing Compounds That Can Be Used in Medicines

The last ten years have seen significant development of new sulfur-containing compounds used in various sectors, including the pharmaceutical and agricultural industries. Sulfoximines, sulfonimidoyl fluorides and sulfonimidamides are types of sulfur-containing chemical compounds that have broad potential as therapeutic drugs. However, the process of synthesizing these compounds is complex and has numerous limitations. In a new article published in Nature Chemistry, researchers at Moffitt Cancer Center describe their development of a new reagent that enables a more efficient approach to producing sulfoximines, sulfonimidoyl fluorides and sulfonimidamides that can be used in medicines.

There are four main chemical approaches commonly used to create sulfoximines, sulfonimidoyl fluorides and sulfonimidamides. Recently, an additional approach called sulfur fluoride exchange (SuFEx) chemistry has attracted attention. But the approach has several limitations to its widespread use, such as the need to use high pressures.

The Moffitt research team wanted to develop a more efficient process for creating sulfoximines, sulfonimidoyl fluorides and sulfonimidamides. Through a variety of experiments and chemical processes, they developed a reagent called t-BuSF that acts as a hub in the SuFEx chemical process for synthesizing these sulfur-containing compounds. Using t-BuSF reduced the number of steps needed to produce these compounds and improved reaction times and the stability of their chemical precursors. The researchers further demonstrated the potential utility of t-BuSF in medicinal chemistry in more than 70 examples and by preparing five therapeutic targets and intermediates. They showed that t-BuSF was able to create these products in high yields and with fewer synthesis steps.

“Given the cost-effectiveness and the chemical space accessible by this reagent platform, it is expected to have positive impacts on the discovery sciences, from the development of new medicines and agrochemicals to the discovery of new ligands, organocatalysts and materials,” said Justin Lopchuk, Ph.D., associate member of the Department of Drug Discovery at Moffitt.

This study was supported by the National Institutes of Health (R35-GM142577, P30-CA076292) and the Chemical Purification, Analysis, and Screening Core Facility of the University of South Florida.

Source link

Cosa vuoi trovare?